Thales’ Next-generation Single-chip Solution Embedded in Samsung’s Latest Flagship Smartphone
16.6.2020 09:00:00 EEST | Business Wire | Press release
The Samsung Galaxy S20 will be the first and only device on the market to feature Thales’ technological breakthrough1 - the world’s first smartphones featuring a secure single-chip solution to support both mobile connectivity and trusted contactless services. The use of this innovative connected eSE offers new possibilities for the next generation of consumer devices that pack a wide range of NFC 2 services including secure payments or transport ticketing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200615005300/en/
copyright Samsung
Growing rapidly in popularity, the eSIM enables effortless remote access to connectivity. Users can manage their mobile subscriptions without having to fit or replace SIM cards. Galaxy S20 users will be able to enjoy seamless mobile connectivity and contactless applications such as payments, transit ticketing and digital ID (including mobile passports and mobile driver licenses) in compliance with the relevant industrial specifications (GSMA, payment and transit organisations). This all-in-one connected eSE also saves further valuable space in smartphones, smartwatches and tablets.
“At Samsung, we’re constantly striving to provide consumers with the most advanced technology that will enable new and exciting experiences that people can trust. We’re excited to partner with Thales to offer Galaxy S20 users a unique solution that will offer seamless connectivity and robust security. The Galaxy S20 boasts the highest level of data protection and encryption with Common Criteria Evaluation Assurance Level (CC EAL) 6+ certification. This demands greater component miniaturization while maintaining an advanced level of security, ably demonstrated by Thales’ single-chip integration of eSE and eSIM.”
Daniel Ahn, Senior Vice President and Head of Mobile Security Team, Mobile Communications Business, Samsung Electronics.
“Continuing eSIM integration by the world’s leading smartphone brands, alongside the launch of next-generation devices such as the Samsung S20 range, will move eSIM-compliant smartphone shipments from 143 million in 2019 to in excess of 509 million in 2024.”
Phil Sealy, Research Director, Digital Security research, ABI Research
“This partnership reflects Samsung’s deep trust in Thales, a world leader in eSIM technology and related subscription management services
. Cutting the number of separate components needed within such devices also streamlines inventory and manufacturing processes, boosting productivity and profitability. Thales is uniquely placed in terms of its relationships with key service providers for contactless applications, including banks, mobile operators, automotive makers, transport providers and governments.”
Emmanuel Unguran, Thales Senior Vice President for Mobile Connectivity Solutions
Related resource: What is an eSIM : 6 illustrated answers infographic
About Thales
Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a pro forma basis including Gemalto over 12 months).
Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments.
PLEASE VISIT
Thales Group
Market page
Download HD photos
1 Availability may vary across markets and models.
2 NFC (Near Field Communication) is a standardized wireless communication technology allowing for data exchange between devices that are a few centimetres distant (up to 5 cm). NFC embedded secure element shipments are expected to reach 473 million units among mobile devices by 2024. Source: ABI Research – March 2020.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200615005300/en/
Contact information
PRESS CONTACT
Thales, Media Relations
Digital Identity and Security
Vanessa Viala
+33 (0)6 07 34 00 34
vanessa.viala@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un
Cranium AI and ISTARI Forge Global Alliance to Drive Enterprise AI Security and Governance21.5.2026 13:00:00 EEST | Press release
Cranium AI, the leading end-to-end AI Security and Governance platform, and ISTARI, a leading cyber resilience advisory firm, today announced a strategic partnership to provide global organizations with an end-to-end AI security & governance solution. As organizations accelerate AI adoption, they face a critical challenge: implementing actionable, operational AI governance while keeping pace with the speed of the AI landscape. This collaboration bridges that gap by merging Cranium’s cutting-edge AI security and governance platform with ISTARI’s deep advisory expertise in cyber risk and operating model design. Together, the firms provide a powerful, end-to-end solution for enterprises navigating the complexities of AI transformation. A Unified Vision for Sustainable AI Governance The partnership is built on a shared mission to move organizations beyond fragmented AI initiatives toward fully operationalized, secure, and governed programs. By combining Cranium’s platform automation with I
Cognite and ABB Collaborate to Integrate Agentic AI into Industrial Applications to Deliver Faster Workflows21.5.2026 13:00:00 EEST | Press release
Cognite, the leader in Industrial AI, today announced a collaboration with ABB to assess how advanced industrial AI and data capabilities can be integrated to solve key use cases in the energy sector. By adding an agentic layer to established industrial applications, including ABB Ability™ SafetyInsight™ and ABB Ability™ AlarmInsight™, using the Cognite Industrial AI and Data platform, the collaboration aims to enable "agent-to-agent" orchestration. Leading energy producer Aker BP has signed on as the first customer to implement this new generation of intelligent offerings as part of its strategy to further increase its current production efficiency of 96% and achieve a production growth target of 525,000 barrels of oil equivalent per day by 2028. Transforming Data into Actionable Business Value By breaking down traditional data silos and shifting to outcome-based software orchestration, the collaboration aims to deliver significant business value to ABB and Cognite customers, includin
BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts21.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that more than 60 abstracts across hematologic malignancies and solid tumors have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago) and the 2026 European Hematology Association (EHA) Congress (June 11–14, Stockholm). Continuing to raise the bar in CLL At ASCO and EHA 2026, BeOne will showcase its hematology leadership with data spanning foundational therapies and next-generation innovation across CLL, mantle cell lymphoma and other B-cell malignancies. The data emphasize impressive long-term outcomes, durability across patient populations, and a disciplined approach to advancing future regimens. Collectively, these data underscore BeOne’s strategy to lead in hematology science and patient impact by setting the standard today – while helping to shape the future of CLL. Amit Agarwal, M.D., Ph.D., Chief Medic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom